<DOC>
	<DOCNO>NCT00643448</DOCNO>
	<brief_summary>Explorative study Atrial Fibrillation patient assess Safety Pharmacokinetics initiation treatment steady state</brief_summary>
	<brief_title>Explorative Study AZD1305 Atrial Fibrillation Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented Atrial Fibrillation stable SR least 2 h maximum 28 day . Sinus rhythm randomisation Haemodynamically unstable condition judge Investigator , systolic BP &lt; 100 mmHg &gt; 180 mmHg , diastolic BP &gt; 105 mmHg randomisation Personal family history Torsades de Pointes ( TdP ) , polymorphic ventricular tachycardia ( PVT ) , sustain ventricular tachycardia , long QT syndrome and/or Brugada syndrome Sinus bradycardia ( &lt; 50 beat per minute ( bpm ) ) randomisation QTc ( Fridericia , QTcF ) &gt; 450 m measure sinus rhythm randomisation , Serum potassium 3.8 5.0 mmol/L plasma potassium 3.6 5.0 mmol/L QRS duration &gt; 120 m randomisation Use antiarrhythmic drug class I and/or III , digitalis glycoside , QT prolong drug and/or drug inhibits CYP3A4 , well St John 's Worth</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>